MARKET

FWP

FWP

Forward Pharma A/S
NASDAQ
3.000
0.000
0.00%
Closed 13:00 11/25 EST
OPEN
2.900
PREV CLOSE
3.000
HIGH
3.000
LOW
2.700
VOLUME
4.01K
TURNOVER
10.03K
52 WEEK HIGH
7.20
52 WEEK LOW
2.700
MARKET CAP
21.27M
P/E (TTM)
-11.0457
1D
5D
1M
3M
1Y
5Y
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains
MT Newswires · 11/08 11:21
European ADRs Move Lower in Wednesday Trading
European ADRs Move Lower in Wednesday Trading
MT Newswires · 09/21 11:10
European ADRs Move Lower in Thursday Trading
European ADRs Move Lower in Thursday Trading
MT Newswires · 09/15 11:20
BRIEF-Forward Pharma A/S Submitted A Request For A Written Decision Regarding Petition For Review Regarding EP2801355 To The EBA
BRIEF-Forward Pharma A/S Submitted A Request For A Written Decision Regarding Petition For Review Regarding EP2801355 To The EBA
Reuters · 09/12 21:39
European ADRs Move Higher in Wednesday Trading
MT Newswires · 04/13 11:05
Forward Pharma GAAP EPS of -$0.02
Forward Pharma press release (NASDAQ:FWP): FY GAAP EPS of -$0.02. At December 31, 2021, the Group had cash and cash equivalents of $70.8M and working capital of $70.8M. "We believe
Seekingalpha · 04/11 04:23
Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2021....
GlobeNewswire · 04/08 21:25
Forward Pharma granted Australian patent linked to multiple sclerosis therapy
The Australian government has awarded Forward Pharma (FWP +4.2%) a key patent linked to multiple sclerosis (MS) therapy. According to the details published by IP Australia Thursday, the patent bearing the application
Seekingalpha · 12/23/2021 16:49
More
About FWP
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Webull offers kinds of Forward Pharma A/S stock information, including NASDAQ:FWP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FWP stock methods without spending real money on the virtual paper trading platform.